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are well established, the value of possible life extensions is not. Estimates of the value 
of a statistical life are of limited relevance to valuing such quality-adjusted longevity 
gains. OBJECTIVES: To estimate older smokers’ willingness to pay (WTP) for quality-
adjusted longevity gains. METHODS: Smokers aged 50–64 completed a computerized 
conjoint-analysis (discrete-choice experiment) survey instrument. Hypothetical longev-
ity proﬁles described restrictions on activities of daily living (ADL) for longevity 
increases between 1 and 4 years. The choice task used to explain to respondents how 
risk reductions could be realized without smoking cessation was through the purchase 
of hypothetical cigarette ﬁlters that had no effect on smoking beneﬁts. The joint 
determination of the type and quantity of ﬁlters was modeled jointly to estimate choice 
of ﬁlter type and demand. WTP for life extensions under speciﬁed ADL restrictions 
then were derived from model parameters. RESULTS: A total of 248 subjects com-
pleted the survey. ADL restrictions are a stronger determinant of WTP than years of 
longevity increases. Valuations of life extensions are positive only for high ADL levels. 
The present-value WTP for a one-year life extension with the ADL level described as 
“You are able to drive and you are able to walk a few blocks” is $126,000 (3% dis-
count rate). For the ADL level “Unable to leave your bed”, the corresponding WTP 
is minus $204,000. CONCLUSIONS: Our results shed new light on the perceived 
value to middle-aged subjects of longevity increases under speciﬁed ADL restrictions. 
The WTP estimates suggest that the net beneﬁts of interventions with modest increases 
in longevity are likely to be positive only if the interventions also yield high quality 
of life.
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BACKGROUND: Since 2006, Dutch children receive a 7-valent pneumococcal con-
jugate vaccine (PCV7) against Streptococcus pneumoniae (pneumococci), a leading 
cause of childhood illnesses. New vaccines, covering a wider range of serotypes, will 
soon be available. OBJECTIVES: To evaluate the cost-effectiveness of 10- and 13-
valent vaccines (PCV10 and PCV13) by calculating quality adjusted life years (QALY) 
and costs, and estimate the cost-utility from the societal perspective. METHODS: A 
Markov model was used to calculate the effects of vaccinating a single cohort of 
newborn children in terms of two non-invasive diseases (pneumonia, acute otitis 
media) and two invasive diseases (meningitis, bacteremia) with associated sequelae 
and mortality. Vaccination effectiveness was estimated using trial data. Scenario 
analysis was conducted to analyze the effects of herd immunity. Probabilistic sensitiv-
ity analysis was carried out on incidences, costs, transition probabilities, utility weights 
and vaccine effectiveness. RESULTS: Assuming equal price per dose, both PCV10 and 
PCV13 were dominant compared to PCV7, with lower costs and more QALYs. Due 
to the larger range of serotypes, PCV13 has the fewest cases of pneumonia, invasive 
diseases and sequelae, and is the most cost-effective treatment, dominant to both other 
treatments. However, the superior effectiveness of PCV10 against the very proliﬁc 
otitis compensates in such a way that the difference in both costs and QALYs between 
PCV10 and PCV13 is much smaller than was expected beforehand. CONCLUSIONS: 
From a cost-utility perspective, PCV7 could be replaced by either one of the new 
vaccines, when they become available. The choice between PCV10 and PCV13 will 
depend primarily on price setting and the importance that is assigned to indirect costs. 
PCV10 prevents more cases of frequent, but cheaper otitis, PCV13 prevents more cases 
of less frequent, but more costly in both money and effects, invasive diseases.
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OBJECTIVES: A vaccine for the prevention of HZ and PHN will soon be available 
in Europe. This study assesses the clinical and economic impact of vaccination in 
Belgium. METHODS: Using a Markov model speciﬁcally developed for Europe, a 
vaccination strategy for the Belgian population aged 60 years was compared to the 
current situation of no vaccination. Most epidemiological, resource utilisation and 
general population data were obtained from Belgian sources. In the absence of Belgian 
data, the proportion of PHN was derived from the General Practitioners Research 
Database analysis in the UK, while HZ/PHN pain split, PHN duration and utility data 
were based on the literature. Outcomes included NNV (numbers needed to vaccinate), 
QALYs gained, HZ and PHN cases avoided, applying a PHN deﬁnition of pain occur-
ring or persisting at least 3 months after rash onset. RESULTS: RESULTS A vaccina-
tion strategy compared to no-vaccination resulted in ICERs of a6,799/QALY gained, 
a1,308/HZ case avoided and a3,842/PHN case avoided over the lifetime of the 60 
population, under a third-party payer perspective. NNV results indicated that 12 and 
35 people must be vaccinated to avoid one case of HZ and PHN respectively. Sub-
group analyses for the 60–69 age group showed ICERs of a5,545/QALY gained, 
a843/HZ case avoided, a2,976/PHN case avoided, and NNVs of 8 and 28 respectively. 
Deterministic sensitivity analyses produced ICERs ranging from a4,959 to a19,052/
QALY gained, with the duration of vaccine efﬁcacy having the biggest impact on 
results. A probabilistic sensitivity analysis showed that the probability of the ICERs 
remaining below a30,000 is 94.5% for the 60 population and 95.9% for the 60–69 
population, conﬁrming the cost-effectiveness of vaccination. CONCLUSIONS: The 
ICERs are well below the commonly accepted threshold of a30,000/QALY gained, 
indicating that a HZ vaccination programme would represent a costeffective interven-
tion for Belgium.
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OBJECTIVES: Following recent successes in reducing measles mortality worldwide, 
the WHO has raised the question of the feasibility and cost-effectiveness of the global 
eradication of measles, allowing the stoppage of routine immunization. We estimated 
the potential economic value of measles eradication for a lower-income country using 
the example of Ghana as a case study. We also considered a post-eradication scenario 
with national stockpiling of a measles vaccine to be used in the event of the re-
 introduction either by accident or bioterrorism. METHODS: We estimated timing of 
measles elimination (cessation of within-country transmission), and the numbers of 
measles cases and deaths from an age-structured dynamic compartmental model. After 
elimination, there would be a residual number of cases imported from neighbors. We 
assumed that global eradication would eliminate this importation beginning in 2020 
through a model horizon of 2049. For Ghana, based on accounting and budget data, 
the estimated cost per routine immunization dose was $2.07 and for doses during 
campaigns was $0.70. RESULTS: The dynamic model predicted that elimination 
would be achieved in Ghana in 2009. Between 2020 and 2049, there would be 1711 
cases and 55 deaths. The aggregate present discounted value (to 2010) of the cost of 
routine immunization over this period would be $25.2 million. If measles were eradi-
cated in 2019 and immunization halted thereafter, Ghana would save this amount. 
However, if there were a perceived need to maintain a stockpile to protect the 20.8 
million children projected to be born over this period, even at $0.70 per dose, it would 
require a shelf life of more than 15 years to be cost-effective. CONCLUSIONS: Despite 
the obvious appeal of the global eradication of measles as a long-term objective, it 
appears unlikely that–even with a post-eradication stockpiling strategy–it would be 
cost-effective to cease ongoing vaccination entirely.
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OBJECTIVES: A novel intradermal vaccine (ID) containing 15 Mg of haemagglutinin 
per dose was speciﬁcally developed to prevent seasonal inﬂuenza in subjects aged 60 
years and over (60). In this population, superior immunogenicity of ID vaccine to 
conventional intramuscular vaccine (IM) has been demonstrated during clinical trials. 
We assessed the clinical outcomes and economic impact of vaccinating 60 with ID 
versus IM vaccines. METHODS: A decision-analytic model compared the cost-
 effectiveness ratios of ID versus IM vaccines. Epidemiological and economic inputs 
were speciﬁc to Slovakia and Czech Republic, whereas vaccine effectiveness rates were 
estimated from international literature and inferred from clinical trials. ID prices were 
hypothetical. Results were reported according to public payer’s perspective. RESULTS: 
In Slovakia, ID vaccination was found to prevent 13,134 inﬂuenza cases, 1,159 hos-
pitalizations and 273 deaths in the 60 population, more than with IM vaccination 
(respectively 11,235 inﬂuenza cases, 991 hospitalizations, 234 deaths). In Czech 
Republic these ﬁgures were respectively 35,691, 3,642 and 584 with ID versus 30,532, 
3,115 and 500 with IM. Higher price of ID versus IM was partially offset by the costs 
saved thanks to disease avoided: an incremental a5 per subject vaccinated with ID in 
Slovakia and a4.4 (CZK118.10) in Czech Republic was required from the payer’s 
perspective. Incremental cost-effectiveness ratios of ID versus IM were a12,852/QALY 
in Slovakia and a10,375/QALY (i.e. CZK278,532/QALY) in Czech Republic. These 
values were below three yearly GDP per capita in these 2 countries and therefore could 
be seen as acceptable for health authorities. In probabilistic sensitivity analyses, 
ID vaccination remained a cost-effective strategy. CONCLUSIONS: In the absence of 
published local guidelines regarding the interpretation of cost-effectiveness ratios, 
we chose to follow WHO guidelines regarding GDP per capita: immunizing the 60 
population with ID in Slovakia and Czech Republic appears as a cost-effective alterna-
tive when compared to IM.
